Abstract

Andrew G. J.*, Veeramani G., Manjanna K. M., Rosy C., Sai Srinivas

ABSTRACT

Nevirapine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) used one of the first – line drug for the highly active anti-retroviral therapy (HAART) in human immunodeficiency virus positive patients. The most frequent adverse events associated with nevirapine are rash, purities to fulminant hepatotoxicity. The skin rashes are usually mild and occur in initial 4-6 weeks of starting the therapy, indicating a need for close monitoring and follow-up of the patient in first few weeks. We hereby, present a case of 46 year old male who developed exfoliative dermatitis after 4 week of therapy.